Alterity Therapeutics (ATHE) Long-Term Deferred Tax (2017 - 2025)

Alterity Therapeutics' Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $31.9 million for Q2 2025.

• In Q2 2025, Long-Term Deferred Tax rose 1.51% year-over-year to $31.9 million; the TTM figure through Jun 2025 stood at $31.9 million (up 1.51% YoY), while the FY2025 annual figure was $31.9 million, up 1.51% from the prior year.
• Long-Term Deferred Tax was $31.9 million for Q2 2025 at Alterity Therapeutics, up from $31.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $31.9 million in Q2 2025 to a low of $29.4 million in Q2 2023.
• Historically, Long-Term Deferred Tax has averaged $30.8 million across 5 years, with a median of $31.5 million in 2024.
• The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax grew 20.68% in 2021, then fell 7.03% in 2022.
• A 5-year view of Long-Term Deferred Tax shows it stood at $31.7 million in 2021, then decreased by 7.03% to $29.5 million in 2022, then retreated by 0.23% to $29.4 million in 2023, then advanced by 6.89% to $31.5 million in 2024, then advanced by 1.51% to $31.9 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $31.9 million (Q2 2025), $31.5 million (Q2 2024), and $29.4 million (Q2 2023), per Business Quant data.